SG171602A1 - Use of antisecretory factors for treating intraocular hypertension - Google Patents

Use of antisecretory factors for treating intraocular hypertension

Info

Publication number
SG171602A1
SG171602A1 SG201102876-8A SG2011028768A SG171602A1 SG 171602 A1 SG171602 A1 SG 171602A1 SG 2011028768 A SG2011028768 A SG 2011028768A SG 171602 A1 SG171602 A1 SG 171602A1
Authority
SG
Singapore
Prior art keywords
antisecretory
intraocular hypertension
antisecretory factors
factors
prevention
Prior art date
Application number
SG201102876-8A
Other languages
English (en)
Inventor
Hans-Arne Hansson
Stefan Lange
Eva Jennische
Original Assignee
Lantmaennen As Faktor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantmaennen As Faktor Ab filed Critical Lantmaennen As Faktor Ab
Publication of SG171602A1 publication Critical patent/SG171602A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG201102876-8A 2006-04-27 2007-04-27 Use of antisecretory factors for treating intraocular hypertension SG171602A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0600932 2006-04-27

Publications (1)

Publication Number Publication Date
SG171602A1 true SG171602A1 (en) 2011-06-29

Family

ID=38561776

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201102876-8A SG171602A1 (en) 2006-04-27 2007-04-27 Use of antisecretory factors for treating intraocular hypertension

Country Status (18)

Country Link
US (2) US8207296B2 (pt)
EP (2) EP2015767B1 (pt)
JP (2) JP5284948B2 (pt)
KR (1) KR20090040404A (pt)
CN (2) CN101432013B (pt)
AU (1) AU2007244004B2 (pt)
BR (1) BRPI0710959B8 (pt)
CA (2) CA2650344C (pt)
DK (2) DK2015767T3 (pt)
ES (2) ES2773945T3 (pt)
IL (1) IL194773A (pt)
MX (1) MX2008013769A (pt)
NZ (2) NZ598426A (pt)
PL (2) PL2468292T3 (pt)
RU (1) RU2458703C2 (pt)
SG (1) SG171602A1 (pt)
WO (1) WO2007126364A2 (pt)
ZA (1) ZA200809115B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008013769A (es) * 2006-04-27 2009-02-03 Lantmaennen As Faktor Ab Uso de factores antisecretores para el tratamiento de hipertension intraocular.
US9220750B2 (en) 2007-04-27 2015-12-29 Lantmannen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
WO2013050795A1 (en) * 2011-10-03 2013-04-11 Femtonics Kft. Use of photoactive compounds
JP6204490B2 (ja) * 2012-12-20 2017-09-27 ラントメネン・アーエス−ファクトール・アーベー 膠芽腫処置における抗分泌性因子（ａｆ）の使用
WO2017009004A1 (en) 2015-07-10 2017-01-19 Lantmännen As-Faktor Ab Process for producing egg yolk with high content of af-16
US11407796B2 (en) 2016-07-18 2022-08-09 Lantmännen As-Faktor Ab Antisecretory factor 17
CA3103164A1 (en) 2018-06-28 2020-01-02 Lantmannen Medical Ab Antisecretory factor for use in treatment and/or prevention of acute respiratory failure
CN112770644A (zh) 2018-09-28 2021-05-07 兰特门内保健食品公司 包含麦芽化小麦的可消耗产品
CN112770643A (zh) 2018-09-28 2021-05-07 兰特门内保健食品公司 包含麦芽化脱壳燕麦的可消耗产品
JP2023518790A (ja) 2020-03-26 2023-05-08 ラントメネン・ファンクショナル・フーズ・アーベー 身体活動時の回復を促進するための麦芽穀類を含む消費可能な製品
EP4615577A1 (en) * 2022-11-08 2025-09-17 Aisa Pharma, Inc. Methods of treating eye pain and eye disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH682716A5 (de) 1992-01-13 1993-11-15 Christian Fricker Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
EP0876483A1 (en) * 1996-01-26 1998-11-11 HSC Research and Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
SE506486C2 (sv) * 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
WO2001005968A1 (en) * 1999-06-21 2001-01-25 Inkine Pharmaceutical Company, Inc. Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor
RU2192898C1 (ru) * 2001-08-16 2002-11-20 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Способ лечения герпетического кератита с изъязвлением
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
MX2008013769A (es) * 2006-04-27 2009-02-03 Lantmaennen As Faktor Ab Uso de factores antisecretores para el tratamiento de hipertension intraocular.
AU2007244005B2 (en) * 2006-04-27 2012-08-02 Lantmannen As-Faktor Ab Further medical uses of antisecretory protein
CN101437533B (zh) * 2006-04-27 2016-10-12 兰特门内阿斯-法克托尔公司 抗分泌蛋白对于治疗间室综合症的应用

Also Published As

Publication number Publication date
WO2007126364A3 (en) 2008-03-06
JP2012153695A (ja) 2012-08-16
CN102633863A (zh) 2012-08-15
CA2771087C (en) 2016-03-15
IL194773A0 (en) 2011-08-01
JP5284948B2 (ja) 2013-09-11
EP2468292B8 (en) 2020-02-26
WO2007126364A8 (en) 2009-07-23
BRPI0710959B8 (pt) 2021-05-25
BRPI0710959A2 (pt) 2012-02-28
US9000125B2 (en) 2015-04-07
ES2773945T3 (es) 2020-07-15
EP2468292A1 (en) 2012-06-27
ZA200809115B (en) 2009-07-29
MX2008013769A (es) 2009-02-03
JP2009535329A (ja) 2009-10-01
DK2468292T3 (da) 2020-03-23
CA2771087A1 (en) 2007-11-08
CN101432013B (zh) 2015-01-07
RU2458703C2 (ru) 2012-08-20
PL2468292T3 (pl) 2020-08-24
US20120283191A1 (en) 2012-11-08
BRPI0710959B1 (pt) 2018-11-06
EP2468292B1 (en) 2019-12-18
KR20090040404A (ko) 2009-04-24
AU2007244004A1 (en) 2007-11-08
CN102633863B (zh) 2014-08-06
US8207296B2 (en) 2012-06-26
CA2650344C (en) 2017-10-31
CN101432013A (zh) 2009-05-13
WO2007126364A2 (en) 2007-11-08
DK2015767T3 (en) 2016-02-08
ES2561945T3 (es) 2016-03-01
PL2015767T3 (pl) 2016-05-31
NZ572255A (en) 2012-03-30
EP2015767B1 (en) 2016-01-06
US20090162296A1 (en) 2009-06-25
AU2007244004B2 (en) 2012-02-09
EP2015767A2 (en) 2009-01-21
RU2008146733A (ru) 2010-06-10
CA2650344A1 (en) 2007-11-08
IL194773A (en) 2015-07-30
NZ598426A (en) 2012-08-31

Similar Documents

Publication Publication Date Title
WO2007126364A3 (en) Use of antisecretory factors for treating intraocular hypertension
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2009047766A3 (en) Composition and method for the treatment or prevention of glaucoma and ocular hypertension
WO2007104541A3 (en) Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
MX2009001062A (es) Agonistas de ep2.
WO2007108968A3 (en) Ophthalmic compositions for treating ocular hypertension
MX2010014233A (es) Compuestos quimicos 251.
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
MXPA03008401A (es) Combinacion de brimonidina y timolol para uso oftalmico, topico.
WO2008029276A8 (en) Compositions and methods for the treatment of ophthalmic disease
WO2004069181A3 (en) Composition for the treatment of intraocular pressure
MY138811A (en) Preventive or therapeutic agent for glaucoma
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007127711A3 (en) Abnormal cannabidiols as agents for lowering intraocular pressure
WO2007146136A3 (en) Ophthalmic compositions for treating ocular hypertension
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
BR0316775A (pt) Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
WO2008055205A3 (en) Pai-1 binding modulators for the treatment of ocular disorders
WO2007045930A3 (en) Modulation of trpv expression levels
WO2008057313A3 (en) Methods of using e2f2 for the treatment of hypertension
WO2006020003A3 (en) Ophthalmic compositions for treating ocular hypertension